

Immuno-oncology: Changing treatment paradigms in renal and urothelial cancer

Thematic Session 06

Sunday, 26 March
10:30 - 12:00

Location: Room Vienna, North Hall (Level 1)

Chairs: M. De Santis, Coventry (GB)
M. Kuczyk, Hanover (DE)

Aims and objectives of this session

This session deals with new immunotherapeutical approaches at renal and bladder cancer. For renal cancer, insights the mechanisms of action, the efficacy of these treatment modalities in comparison with established TKI therapy for different indications including the application within a sequential setting should be delivered. For bladder cancer, it should become obvious to what extent and for which indications immunotherapeutic approaches can be expected to replace conventional approaches at the treatment of metastatic disease.

10:30 - 10:40

State-of-the-art lecture Immunotherapy - Impact from oncologist's point of view
T. Powles, London (GB)

10:40 - 10:50

State-of-the-art lecture Immunotherapy - Impact from surgeon's point of view
F-C.E. Von Rundstedt, Jena (DE)

10:50 - 11:00

State-of-the-art lecture Immunotherapy - Open questions and trials
L. Albiges, Villejuif (FR)

11:00 - 11:10

Discussion

11:10 - 12:00

Urothelial cancer

11:10 - 11:25

State-of-the-art lecture Biomarkers for treatment selection
S. Shariat, Vienna (AT)

11:25 - 11:40

State-of-the-art lecture Is there still a role for chemotherapy?
A. Bamias, Athens (GR)

11:40 - 11:55

State-of-the-art lecture How will immunotherapy change the treatment paradigm?
R. Jones, Glasgow (GB)

11:55 - 12:00

Discussion